company background image
AVIR

Atea Pharmaceuticals NasdaqGS:AVIR Stock Report

Last Price

US$5.76

Market Cap

US$479.6m

7D

4.7%

1Y

-87.1%

Updated

03 Oct, 2022

Data

Company Financials +
AVIR fundamental analysis
Snowflake Score
Valuation4/6
Future Growth3/6
Past Performance2/6
Financial Health6/6
Dividends0/6

AVIR Stock Overview

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections.

Atea Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Atea Pharmaceuticals
Historical stock prices
Current Share PriceUS$5.76
52 Week HighUS$46.91
52 Week LowUS$5.31
Beta0
1 Month Change-22.69%
3 Month Change-23.10%
1 Year Change-87.08%
3 Year Changen/a
5 Year Changen/a
Change since IPO-81.02%

Recent News & Updates

Sep 26

Atea wins FDA Fast Track status for dengue treatment

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR), a biotech focused on developing treatments for viral infections, announced Monday that the FDA granted Fast Track Designation to AT-752, an investigational oral therapy for dengue virus infection. Dengue is the most common mosquito-borne virus in the world, affecting an estimated up to 400M people annually. The FDA offers the Fast Track designation to accelerate the development and review of drugs targeted at serious conditions with unmet medical needs. It allows developers to communicate frequently with the regulator on plans for clinical studies. Developed using AVIR’s purine nucleotide prodrug platform, AT-752 is currently undergoing two proof-of-concept studies for dengue, with data expected at the end of the year. Read more on upcoming milestones for AVIR as outlined by the management in August.

Shareholder Returns

AVIRUS PharmaceuticalsUS Market
7D4.7%-0.04%-2.5%
1Y-87.1%3.2%-23.2%

Return vs Industry: AVIR underperformed the US Pharmaceuticals industry which returned 3.2% over the past year.

Return vs Market: AVIR underperformed the US Market which returned -23.2% over the past year.

Price Volatility

Is AVIR's price volatile compared to industry and market?
AVIR volatility
AVIR Average Weekly Movement6.4%
Pharmaceuticals Industry Average Movement11.3%
Market Average Movement6.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: AVIR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: AVIR's weekly volatility has decreased from 13% to 6% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201263Jean-Pierre Sommadossihttps://ateapharma.com

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection.

Atea Pharmaceuticals Fundamentals Summary

How do Atea Pharmaceuticals's earnings and revenue compare to its market cap?
AVIR fundamental statistics
Market CapUS$479.57m
Earnings (TTM)US$15.53m
Revenue (TTM)US$224.99m

30.9x

P/E Ratio

2.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AVIR income statement (TTM)
RevenueUS$224.99m
Cost of RevenueUS$150.32m
Gross ProfitUS$74.67m
Other ExpensesUS$59.14m
EarningsUS$15.53m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.19
Gross Margin33.19%
Net Profit Margin6.90%
Debt/Equity Ratio0%

How did AVIR perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is AVIR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AVIR?

Other financial metrics that can be useful for relative valuation.

AVIR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ratio0.7x

Price to Earnings Ratio vs Peers

How does AVIR's PE Ratio compare to its peers?

AVIR PE Ratio vs Peers
The above table shows the PE ratio for AVIR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average45.6x
AMYT Amryt Pharma
158.6x75.3%US$444.1m
PAHC Phibro Animal Health
11.3x1.4%US$557.3m
SIGA SIGA Technologies
10.3x-22.2%US$739.0m
BTMD biote
2.3x-25.8%US$290.0m
AVIR Atea Pharmaceuticals
30.9x47.2%US$473.7m

Price-To-Earnings vs Peers: AVIR is good value based on its Price-To-Earnings Ratio (30.9x) compared to the peer average (45.6x).


Price to Earnings Ratio vs Industry

How does AVIR's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Earnings vs Industry: AVIR is expensive based on its Price-To-Earnings Ratio (30.9x) compared to the US Pharmaceuticals industry average (12.4x)


Price to Earnings Ratio vs Fair Ratio

What is AVIR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AVIR PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio30.9x
Fair PE Ratio39.4x

Price-To-Earnings vs Fair Ratio: AVIR is good value based on its Price-To-Earnings Ratio (30.9x) compared to the estimated Fair Price-To-Earnings Ratio (39.4x).


Share Price vs Fair Value

What is the Fair Price of AVIR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AVIR ($5.76) is trading below our estimate of fair value ($176.22)

Significantly Below Fair Value: AVIR is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Atea Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

3/6

Future Growth Score 3/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


47.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AVIR's forecast earnings growth (47.2% per year) is above the savings rate (1.9%).

Earnings vs Market: AVIR's earnings (47.2% per year) are forecast to grow faster than the US market (14.8% per year).

High Growth Earnings: AVIR's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: AVIR's revenue (5.2% per year) is forecast to grow slower than the US market (7.7% per year).

High Growth Revenue: AVIR's revenue (5.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AVIR's Return on Equity is forecast to be low in 3 years time (5.3%).


Discover growth companies

Past Performance

How has Atea Pharmaceuticals performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


83.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: AVIR has high quality earnings.

Growing Profit Margin: AVIR's current net profit margins (6.9%) are lower than last year (20.2%).


Past Earnings Growth Analysis

Earnings Trend: AVIR's earnings have grown significantly by 83.3% per year over the past 5 years.

Accelerating Growth: AVIR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: AVIR had negative earnings growth (-56%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (5%).


Return on Equity

High ROE: AVIR's Return on Equity (2.4%) is considered low.


Discover strong past performing companies

Financial Health

How is Atea Pharmaceuticals's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: AVIR's short term assets ($689.5M) exceed its short term liabilities ($25.1M).

Long Term Liabilities: AVIR's short term assets ($689.5M) exceed its long term liabilities ($8.8M).


Debt to Equity History and Analysis

Debt Level: AVIR is debt free.

Reducing Debt: AVIR has not had any debt for past 5 years.

Debt Coverage: AVIR has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: AVIR has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Atea Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Atea Pharmaceuticals Dividend Yield vs Market
How does Atea Pharmaceuticals dividend yield compare to the market?
SegmentDividend Yield
Company (Atea Pharmaceuticals)n/a
Market Bottom 25% (US)1.7%
Market Top 25% (US)4.7%
Industry Average (Pharmaceuticals)2.6%
Analyst forecast in 3 Years (Atea Pharmaceuticals)n/a

Notable Dividend: Unable to evaluate AVIR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AVIR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AVIR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AVIR's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as AVIR has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

Jean-Pierre Sommadossi (66 yo)

10.25yrs

Tenure

US$34,104,892

Compensation

Dr. Jean-Pierre Sommadossi, Ph D., is a Founder of Atea Pharmaceuticals, Inc. and has been its Chairman, Director, Chief Executive Officer and President since July 2012 and had been its Treasurer. Dr. Somm...


CEO Compensation Analysis

Jean-Pierre Sommadossi's Compensation vs Atea Pharmaceuticals Earnings
How has Jean-Pierre Sommadossi's remuneration changed compared to Atea Pharmaceuticals's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

US$16m

Mar 31 2022n/an/a

US$48m

Dec 31 2021US$34mUS$650k

US$121m

Sep 30 2021n/an/a

US$25m

Jun 30 2021n/an/a

US$35m

Mar 31 2021n/an/a

US$24m

Dec 31 2020US$3mUS$437k

-US$11m

Sep 30 2020n/an/a

-US$36m

Jun 30 2020n/an/a

-US$22m

Mar 31 2020n/an/a

-US$16m

Dec 31 2019US$811kUS$400k

-US$14m

Compensation vs Market: Jean-Pierre's total compensation ($USD34.10M) is above average for companies of similar size in the US market ($USD2.94M).

Compensation vs Earnings: Jean-Pierre's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Leadership Team

Experienced Management: AVIR's management team is considered experienced (2.2 years average tenure).


Board Members

Experienced Board: AVIR's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

NasdaqGS:AVIR Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
20 Dec 21BuyUS$102,796Polly MurphyIndividual12,000US$8.57

Ownership Breakdown

What is the ownership structure of AVIR?
Owner TypeNumber of SharesOwnership Percentage
Hedge Funds6,340,6397.6%
Individual Insiders7,583,8269.1%
General Public17,531,04221.1%
Institutions51,803,09662.2%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 71.72% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
15.06%
FMR LLC
12,539,475$72.2m-0.32%0.01%
8.9%
BlackRock, Inc.
7,407,542$42.7m11.82%no data
8.62%
The Vanguard Group, Inc.
7,180,285$41.4m6.7%no data
7.62%
EcoR1 Capital, LLC
6,340,639$36.5m0%0.99%
7.12%
Jean-Pierre Sommadossi
5,925,000$34.1m0%no data
4.31%
Federated Hermes, Inc.
3,588,131$20.7m74.92%0.06%
2.99%
Bain Capital Life Sciences Investors, LLC
2,485,638$14.3m0%1.56%
2.17%
State Street Global Advisors, Inc.
1,803,368$10.4m-3.67%no data
2.16%
Balyasny Asset Management L.P.
1,799,507$10.4m16317.36%0.05%
1.93%
K2 & Associates Investment Management Inc.
1,606,059$9.3m0%1.76%
1.86%
Cormorant Asset Management, LP
1,547,181$8.9m0%0.61%
1.39%
Geode Capital Management, LLC
1,161,424$6.7m12.9%no data
0.98%
Franklin Berger
820,019$4.7m0%no data
0.86%
Acadian Asset Management LLC
714,422$4.1m-16.2%0.02%
0.83%
Northern Trust Global Investments
693,126$4.0m23.77%no data
0.8%
Renaissance Technologies LLC
663,000$3.8m-43.09%no data
0.76%
Andrea Corcoran
633,004$3.6m0%no data
0.52%
Jacobs Levy Equity Management Inc
432,438$2.5m181.53%0.02%
0.51%
Charles Schwab Investment Management, Inc.
427,721$2.5m3.17%no data
0.46%
PGIM, Inc.
379,335$2.2m-15.16%no data
0.42%
Bridgeway Capital Management, LLC
347,612$2.0m1201.92%0.05%
0.41%
Banque Pictet & Cie S.A., Asset Management Arm
345,077$2.0m0%0.02%
0.4%
Morgan Stanley, Investment Banking and Brokerage Investments
335,631$1.9m-21.53%no data
0.32%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
270,163$1.6m6.78%no data
0.32%
BNY Mellon Asset Management
270,044$1.6m-2.41%no data

Company Information

Atea Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Atea Pharmaceuticals, Inc.
  • Ticker: AVIR
  • Exchange: NasdaqGS
  • Founded: 2012
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$479.570m
  • Shares outstanding: 83.26m
  • Website: https://ateapharma.com

Number of Employees


Location

  • Atea Pharmaceuticals, Inc.
  • 125 Summer Street
  • Boston
  • Massachusetts
  • 2110
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AVIRNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 2020

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/03 00:00
End of Day Share Price2022/10/03 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.